Allan Shepard

Allan is a molecular biologist with over 22 years of combined experience in basic, pre-clinical, and clinical drug research and development. Allan spent the first 14 years of his career at Alcon/Novartis as Head of In Vitro Pharmacology focused on Ophthalmology therapeutics. He followed this by becoming a biotechnology entrepreneur with EyeOPx and Element Diagnostics. Prior to joining Eleusis, Allan was Clinical Project Manager for Phase I-III trials with CRO's Catawba Research and Parexel. He has also authored 31 peer-reviewed scientific publications, 20 patents (issued or pending), and 10 global (US/Latin America/Canada/India) clinical trials with FDA and Health Canada approvals.

Allan received his PhD in Molecular Biology from Mayo Clinic and BS in Biochemistry from the University of Iowa.